COPD

At ATS, Klaus Friedrich Rabe, MD, PhD, discussed phase 3 data on itepekimab in former smokers with chronic obstructive pulmonary disease (COPD).

Experts unpack new asthma/COPD biologics, eosinophil+FeNO targeting, twice-yearly depemokimab switching, and payer hurdles in 2026 care.

At ATS 2026, investigators reported that pediatric pulmonary rehabilitation improved exercise capacity and quality of life in chronic respiratory disease.

Clinicians at ATS 2026 will see late-breaking COPD, asthma, and pulmonary hypertension data alongside exclusive interviews with leading experts in respiratory medicine.

Stay updated with the latest healthcare breakthroughs, including FDA actions and new topline clinical trial data, in this week’s essential news roundup.

Phase 3 MIRANDA found tozorakimab reduced COPD exacerbations in former smokers despite inhaled maintenance therapy.

Experts unpack new T2-targeted biologics for severe asthma and eosinophilic COPD, sharing biomarker tips, sequencing debates and payer hurdles,

The Q1 recap for pulmonology spotlights regulatory and clinical advances across asthma and pulmonary fibrosis.

March 2026 saw new data from pivotal clinical trials and new expert conversations on HCPLive.

AstraZeneca's investigational IL-33–targeting antibody tozorakimab met its primary endpoint in both the phase III OBERON and TITANIA trials.

Clinicians compare newest asthma/COPD biologics, highlighting dupilumab’s edge, biomarker shifts, and insurance barriers shaping real-world use.

New biologics transform severe asthma and COPD, yet prednisone overuse persists—see practical selection tips and outpatient steroid stewardship gaps.

Experts weigh new biologics including dupilumab, tezepelumab, and depemokimab, and how eosinophils guide real-world prescribing.

February 2026 saw new data and expert interviews from AAAAI 2026.

A new study stratified patients by longitudinal BEC patterns to assess whether variability in eosinophil levels influences response.

Claims study suggests dry powder and soft mist COPD inhalers cut exacerbations versus MDIs, offering greener care without added safety risks.